Insiders At Intellia Therapeutics Sold US$975k In Stock, Alluding To Potential Weakness

Simply Wall St53minutes ago

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

Zacks Jan 17 13:00 ET

BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $45

Moomoo NewsJan 14 10:32 ET · Ratings

Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $12

Moomoo NewsJan 14 10:32 ET · Ratings

Express News | Goldman Sachs Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $12

BenzingaJan 14 09:10 ET

A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $40 to $45

Moomoo NewsJan 14 08:00 ET · Ratings